论文部分内容阅读
运用功能纳米颗粒的药物发送系统是一种具有发展前景的途径,因为它减少了副反应并减轻病痛 Poly(D,L lactide co glycolide)(PLGA)纳米颗粒的尺寸是80nm,它的制备是通过乳化扩散方法,并应用Poloxamer188作为稳定剂 所制备的纳米颗粒具有疏水核作为药物的载体,而其冠状亲水表面可避免形成网状内皮系统(RES) 作为生物医学应用的第一个例子是PLAG纳米颗粒包含雌激素,它对于受到意外伤害而抑制不安情绪具有局限性 研究指出:局部地发送具有雌激素的PLGA纳米颗粒将激烈减少新内膜的形成程度 其次是应用经过修改的PLAG纳米颗粒发送系统专用于骨治疗的药已经实现,它与骨有高度的相似 已经证明:与双磷酸(bisphosphonate)相结合的PLGA纳米颗粒,参入到鼠的静脉内之后,将可累积在鼠骨内
A drug delivery system using functional nanoparticles is a promising approach because it reduces side effects and alleviates pain Poly (D, L lactide co glycolide) (PLGA) nanoparticles are 80 nm in size and are prepared by Emulsification diffusion method and using Poloxamer188 as a stabilizer Nanoparticles prepared with a hydrophobic core as a drug carrier and a coronally hydrophilic surface that avoids the formation of a reticuloendothelial system (RES) as the first example for biomedical applications PLAG Nanoparticles contain estrogen, which has limitations in suppressing unpleasant feelings of unintentional injury Studies have shown that locally delivering PLGA nanoparticles with estrogen will drastically reduce the extent of neointima formation followed by sending with modified PLAG nanoparticles System-specific bone-treatment drugs have been achieved and are highly similar to bone. It has been demonstrated that PLGA nanoparticles conjugated to bisphosphonate will accumulate in the rat bone after their incorporation into the rat’s vein